Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.
This session starts with Mike who shares a compelling anecdote around the ongoing challenges which persist in the post-recovery of NAFLD. Specifically, he suggests the document made light of bariatric surgery as a treatment option and failed to consider the extent of preparations and persistence which it requires. Wayne expands on his disappointment with the fact that the document does not consider NAFLD/NASH as a progressive disease. As a numbers guy, Tony explains that he chose to discuss the significant fallacies in the populations and numbers chosen for the economic analysis.
If you enjoy the episode, have questions or interest around endocrinology and Fatty Liver disease, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!